These ratings are submitted by site users and should be used for information only.
They do not constitute any instruction to trade and do not reflect the opinion of this site.
What do the charts indicate?
The colour of the lines on the chart indicate the performance of the rating based upon the price at the point the rating was submitted. More information »
In view of Zak Mir's projected target of 60p and his advice that even the most cautious should take the plunge at 34p, I see these shares surging big time. Last time Zak Mir advised a pile in at a specific price there was a buying frenzy. My verdict: SUPER STRONG BUY
Sareum now has excellent prospects for funding their pipeline of preclinical molecules following their recent deal. As the market for kinase inhibitors gets ever hotter expect this company to be the focus of further industry attention.